duvortuxizumab

Duvortuxizumab (MGD011) is a bispecific Dual-Affinity Re-Targeting (DART) molecule designed to simultaneously target CD19 and CD3. Developed by MacroGenics in collaboration with Janssen Biotech, the therapeutic was engineered to redirect T cells to eliminate malignant B cells expressing CD19. It was primarily investigated for the treatment of various B-cell hematological malignancies, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL). In December 2014, Janssen licensed the global rights to the molecule for a $50 million upfront payment and a $75 million equity investment. However, Janssen terminated the agreement in August 2017 following safety concerns, specifically treatment-related neurotoxicity observed during Phase 1 dose-escalation trials. MacroGenics regained worldwide rights to the asset in 2018, but the program has since been deprioritized.

Other names

CD19 x CD3 DART moleculeCD-19 x CD3 DART moleculeCD 19 x CD3 DART moleculeJNJ-64052059JNJ64052059JNJ 64052059